← Research library

Peptide substance restoring myocardium function — US7662789B2

Patent disclosure · 2010

What the patent describes
Cardiogen/AEDR animal and isolated-cardiomyocyte studies; no human cardiac-treatment cohort established in this patent review.
Reported evidence
Original patent behind the rat-infarction claim in the 2023 cardiovascular review. Kept separate from clinical evidence and peer-reviewed primary experiments.

Succinate-related respiration coefficient · 7.35 ± 0.26 in oxygen-deprived cells versus 1.97 ± 0.26 after peptide · Cellular respiration ratio; oxygen consumption in normally oxygenated cells was not altered

Reported patent results

Reported findings

The patent reports altered cellular respiration under oxygen deprivation and leukocyte changes in longer animal observations.

Cardiogen/AEDR animal and isolated-cardiomyocyte studies; no human cardiac-treatment cohort established in this patent review.

Population or model Cardiogen/AEDR animal and isolated-cardiomyocyte studies; no human cardiac-treatment cohort established in this patent review.

Results · Isolated-cardiomyocyte respiration narrative and longer-term Table 9.
MeasureResultComparison, timing and statistics
Succinate-related respiration coefficient7.35 ± 0.26 in oxygen-deprived cells versus 1.97 ± 0.26 after peptideCellular respiration ratio; oxygen consumption in normally oxygenated cells was not altered
Animal leukocytes11.2 ± 0.8 versus 9.4 ± 0.5 control at 3 months; 11.9 ± 0.5 versus 9.6 ± 0.5 at 6 months×10^9/L; 24 animals per displayed group · p<0.05

Cellular bioenergetics and animal blood counts do not establish improved cardiac outcomes in patients. A leukocyte change is not interchangeable with an absence of biological effects.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Molecule. The claim concerns Ala-Glu-Asp-Arg (AEDR), the Cardiogen sequence; EP1758923 belongs to this family and is not the respiratory AEDL peptide.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US7662789B2 ↗ · 2010-02-16
Earliest priority / filing
2004-06-22 / 2004-12-07
Original applicant / assignee
Access Bioscience CJSC
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
34960195 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide substance restoring myocardium function

Inventors: Vladimir Khatskelevich Khavinson; Galina Anatolievna Ryzhak; Evgeny Iosifovich Grigoriev; Irina Yurievna Ryadnova.

US7662789B2 · EP1758923B8 · ATE386047T1 · DE602004011843T2 · ES2302067T3 · RU2255756C1 · WO2006001728A1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent claims are not independent validation.
  • No human cardiovascular benefit is established by this source.

Source details

Patent identity and its citation as reference 123 in the review checked; detailed experimental appraisal pending.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

V. Kh. Khavinson, G. A. Ryzhak, E. I. Grigoriev, I. Yu. Ryadnova. Peptide substance restoring myocardium function — US7662789B2 US patent 7,662,789 B2

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards